Invitae (NVTA) Is Invitae A Buy?

Invitae (NVTA) announced preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year. Invitae Corp. (NVTA), a leading medical genetics company, announced preliminary unaudited …

Invitae (NVTA) Is Invitae A Buy? Read More »